专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08354448B2 Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetes 有权
标题翻译：（ - ）（3-三卤甲基苯氧基）（4-卤苯基）乙酸衍生物用于治疗2型糖尿病
公开(公告)号：US08354448B2
公开(公告)日：2013-01-15
申请号：US12504487
申请日：2009-07-16
申请人： Kenneth L. Luskey , Jian Luo
发明人： Kenneth L. Luskey , Jian Luo
IPC分类号： A61K31/20
CPC分类号： A61K31/216 , A61K31/075 , A61K31/19 , A61K31/195 , A61K31/215 , A61K31/235 , A61K31/425 , A61K31/455 , A61K31/64 , A61K38/28 , A61K45/06 , Y10S514/866 , Y10S514/891 , A61K31/155 , A61K2300/00
摘要： The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.
摘要翻译：本发明提供（ - ）（3-三卤甲基苯氧基）（4-卤代苯基）乙酸衍生物和组合物在治疗胰岛素抵抗，2型糖尿病和高脂血症中的用途。

2. 发明授权

US07087223B2 Preventives and/or remedies for hyperphosphatemia 失效
公开(公告)号：US07087223B2
公开(公告)日：2006-08-08
申请号：US10984149
申请日：2004-11-09
申请人： Takeshi Goto , Kazuhisa Yoshitake , Hiroshi Sorimachi , Kazuteru Moriyama
发明人： Takeshi Goto , Kazuhisa Yoshitake , Hiroshi Sorimachi , Kazuteru Moriyama
IPC分类号： A61K31/78 , A61K31/785 , A61P3/00 , A61P3/12 , A61P13/12
CPC分类号： A61K31/787 , A61K31/78 , Y10S514/814 , Y10S514/824 , Y10S514/891
摘要： Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect of lowering blood phosphorus level and another effect of suppressing phosphorus excretion into the urine.

3. 发明授权

US06242230B1 Process for microencapsulating cells 失效
标题翻译：微胶囊化细胞的方法
公开(公告)号：US06242230B1
公开(公告)日：2001-06-05
申请号：US09442925
申请日：1999-11-18
申请人： Chris Batich , Farid Vaghefi
发明人： Chris Batich , Farid Vaghefi
IPC分类号： C12N1100
CPC分类号： A61K9/1652 , A61K9/5026 , A61K9/5031 , A61K9/5073 , A61K35/74 , C12N11/04 , Y10S514/866 , Y10S514/891 , Y10S514/963 , Y10S514/965
摘要： Oxalate-degrading enzymes and bacteria were encapsulated for both enteric and intraperitoneal administration. We have shown that via alginate microencapsulation of Oxalobacter formigenes, enzymatic activity was retained for several months. A new process was developed which strengthened the alginate microcapsules and their tolerance to citrate treatment. Much smaller (30-50 &mgr;m) alginate microcapsules were made for injection as means of implantation. For oral administration, multi-encapsulated microspheres of cellulose acetate phthalate in poly-2-vinylpyridine (pKa=3.5) were prepared to protect the enzymes from gastric juices.
摘要翻译：将生物降解酶和细菌包封以进行肠溶和腹膜内给药。我们已经表明，通过藻酸盐微胶囊化生物标记物，酶活性保留了数月。开发了一种加强藻酸盐微胶囊及其对柠檬酸盐处理的耐受性的新工艺。制备更小的（30-50um）藻酸盐微胶囊用于注射作为植入手段。对于口服给药，制备聚-2-乙烯基吡啶（pKa = 3.5）中的邻苯二甲酸纤维素的多包封微球体，以保护酶免于胃液。

4. 发明授权

US6033888A Process for microencapsulating cells 失效
标题翻译：微胶囊化细胞的方法
公开(公告)号：US6033888A
公开(公告)日：2000-03-07
申请号：US891189
申请日：1997-07-10
申请人： Chris Batich , Farid Vaghefi
发明人： Chris Batich , Farid Vaghefi
IPC分类号： A61K9/16 , A61K9/50 , A61K9/52 , A61K35/12 , A61K35/74 , C12N11/04 , C12N11/10 , B01J13/22
CPC分类号： A61K9/1652 , A61K35/74 , A61K9/5026 , A61K9/5031 , A61K9/5073 , C12N11/04 , Y10S514/866 , Y10S514/891 , Y10S514/963 , Y10S514/965
摘要： Oxalate-degrading enzymes and bacteria were encapsulated for both enteric and intraperitoneal administration. We have shown that via alginate microencapsulation of Oxalobacter formigenes, enzymatic activity was retained for several months. A new process was developed which strengthened the aliginate microcapsules and their tolerance to citrate treatment. Much smaller (30-50 .mu.m) aliginate microcapsules were made for injection as means of impantation. For oral administration, multi-encapsulated microspheres of cellulose acetate phthalate in poly-2-vinylpyridine (pKa=3.5) were prepared to protect the enzymes from gastric juices.
摘要翻译：将生物降解酶和细菌包封以进行肠溶和腹膜内给药。我们已经表明，通过藻酸盐微胶囊化生物标记物，酶活性保留了数月。开发了一种新方法，加强了血浆微胶囊及其对柠檬酸盐治疗的耐受性。制备更小的（30-50微米）的凝胶微胶囊作为注射的手段。对于口服给药，制备聚-2-乙烯基吡啶（pKa = 3.5）中的邻苯二甲酸纤维素的多包封微球体，以保护酶免于胃液。

5. 发明授权

US5604103A Kit for detection of clinical marker in kidney stone disease 失效
标题翻译：用于检测肾结石疾病临床标志物的试剂盒
公开(公告)号：US5604103A
公开(公告)日：1997-02-18
申请号：US261581
申请日：1994-06-17
申请人： William C. Thomas, Jr. , Christopher D. Batich , Daniel L. Purich
发明人： William C. Thomas, Jr. , Christopher D. Batich , Daniel L. Purich
IPC分类号： G01N31/00 , A61K31/335 , A61K31/357 , A61K31/365 , A61K31/495 , A61K31/535 , A61P1/16 , A61P7/02 , A61P9/10 , A61P13/02 , A61P15/00 , C07D241/18 , C07D319/12 , G01N33/493 , G01N33/50 , G01N33/53 , G01N33/52
CPC分类号： A61K31/365 , C07D319/12 , G01N33/493 , Y10S435/975 , Y10S514/891 , Y10T436/142222 , Y10T436/200833
摘要： Dicitrate cyclic diester (dicitrate) is a novel compound which is found in patients who do not exhibit symptoms or predisposition to idiopathic renal calculous disease. Kits are provided for the detection of dicitrate cyclic diester.
摘要翻译：糖尿病环状二酯（dicitrate）是一种新型化合物，在不显示特发性肾结石病症状或倾向的患者中发现。提供试剂盒用于检测甘油二酯环状二酯。

6. 发明授权

US5591724A Method for treating the urinary bladder and associated structures using hyaluronic acid 失效
标题翻译：使用透明质酸治疗膀胱和相关结构的方法
公开(公告)号：US5591724A
公开(公告)日：1997-01-07
申请号：US388038
申请日：1995-02-14
申请人： Alvaro Morales , Stanley J. Alkemade
发明人： Alvaro Morales , Stanley J. Alkemade
IPC分类号： A61K31/728 , A61K31/73 , A61K47/36
CPC分类号： A61K31/728 , Y10S514/891
摘要： A method of treating interstitial cystitis comprising contacting the internal bladder and associated structures in a mammal having interstitial cystitis with a solution containing hyaluronic acid having a molecular weight of not less than approximately 2.times.10.sup.5 Daltons in a concentration effective to treat the interstitial cystitis.
摘要翻译：一种治疗间质性膀胱炎的方法，其特征在于，将具有间质性膀胱炎的哺乳动物的内部膀胱和相关结构与含有分子量不小于约2×10 5道尔顿的透明质酸的溶液以有效治疗间质性膀胱炎的浓度接触。

7. 发明授权

US5550259A Clinical marker and therapeutic agent in kidney stone disease and methods of use 失效
标题翻译：肾结石病的临床标志物和治疗剂及其使用方法
公开(公告)号：US5550259A
公开(公告)日：1996-08-27
申请号：US460585
申请日：1995-06-02
申请人： William C. Thomas, Jr. , Christopher D. Batich , Daniel L. Purich
发明人： William C. Thomas, Jr. , Christopher D. Batich , Daniel L. Purich
IPC分类号： G01N31/00 , A61K31/335 , A61K31/357 , A61K31/365 , A61K31/495 , A61K31/535 , A61P1/16 , A61P7/02 , A61P9/10 , A61P13/02 , A61P15/00 , C07D241/18 , C07D319/12 , G01N33/493 , G01N33/50 , G01N33/53
CPC分类号： A61K31/365 , C07D319/12 , G01N33/493 , Y10S435/975 , Y10S514/891 , Y10T436/142222 , Y10T436/200833
摘要： Dicitrate cyclic diester (dicitrate) is a novel compound which is found in patients who do not exhibit symptoms or predisposition to idiopathic renal calculous disease. Dicitrate can be isolated and detected by novel chromatographic methods. Further, treating patients prophylactically and therapeutically with dicitrate cyclic diester can prevent or reduce the effects of calcification-related disease, including some types of kidney stones, or other disease or condition associated with the presence of metal ions. The metal ion complexing properties exhibited by dicitrate are also applicable to the use of the subject compounds as chelating agents and methods of binding, and thereby reducing, the amounts of metal ions in a substance.
摘要翻译：糖尿病环状二酯（dicitrate）是一种新型化合物，在不显示特发性肾结石病症状或倾向的患者中发现。可以通过新的色谱方法分离和检测赤霉素。此外，预防和治疗患者用赤霉素环状二酯可以预防或减少钙化相关疾病（包括某些类型的肾结石）或与金属离子存在相关的其他疾病或病症的作用。由赤霉素显示的金属离子络合性质也适用于本发明化合物作为螯合剂的使用以及结合物质的方法，从而减少物质中金属离子的量。

8. 发明授权

US4851221A Liquid calcium supplementation from readily soluble mixtures of calcium compound and citric acid 失效
标题翻译：从钙化合物和柠檬酸的易溶混合物中补充液体钙
公开(公告)号：US4851221A
公开(公告)日：1989-07-25
申请号：US935666
申请日：1986-11-26
申请人： Charles Y. C. Pak , Neill B. Walsdorf
发明人： Charles Y. C. Pak , Neill B. Walsdorf
IPC分类号： A23L2/52 , A23L1/304 , A23L2/38 , A23L2/68 , A61K31/00 , A61K31/19 , A61K33/06 , A61P3/00 , A61P3/02 , A61P3/14 , A61P43/00
CPC分类号： A23L2/68 , A23L2/38 , A23L33/16 , A61K31/19 , A61K33/06 , Y10S514/891
摘要： The present invention comprises a composition of matter consisting essentially of citric acid and one or more calcium compounds selected from the group consisting of calcium hydroxide, calcium carbonate and calcium oxide. The composition of matter is preferably a substantially dry mixture which may be used, for example, as a powder for making an "instant" beverage of potable liquid. A preferred calcium compound/citric acid molar ratio in the composition of matter of the present invention is between about 0.6 and about 1.5.In a most preferred embodiment, the composition of matter of the present invention consists essentially of calcium hydroxide and citric acid having a calcium compound/citric acid or calcium hydroxide/citric acid molar ratio of about 1.25.The composition of matter of the present invention has a utility demostrated by dissolution in water to form a liquid dietary calcium supplement comprising soluble calcium citrate. This composition of matter may comprise one or more of a flavorant, lubricant, sweetener or colorant usable to maintain a powdery texture or to enhance the flavor of a beverage prepared therefrom.
摘要翻译：本发明包括基本上由柠檬酸和一种或多种选自氢氧化钙，碳酸钙和氧化钙的钙化合物组成的物质组合物。物质的组成优选为基本上干燥的混合物，其可以用作例如用于制造饮用液体的“即时”饮料的粉末。本发明物质组合物中优选的钙化合物/柠檬酸摩尔比为约0.6至约1.5。在最优选的实施方案中，本发明的物质组成基本上由具有约1.25的钙化合物/柠檬酸或氢氧化钙/柠檬酸摩尔比的氢氧化钙和柠檬酸组成。本发明的物质组成具有通过在水中溶解形成含有可溶性柠檬酸钙的液体膳食钙补充剂的功效。该物质组合物可以包含一种或多种调味剂，润滑剂，甜味剂或着色剂，其可用于保持粉末质地或增强由其制备的饮料的风味。

9. 发明授权

US4849452A Nephro-urological medicament 失效
标题翻译：肾脏泌尿药
公开(公告)号：US4849452A
公开(公告)日：1989-07-18
申请号：US808014
申请日：1985-12-11
申请人： Hans-Joachim Dulce , Werner Stumpf
发明人： Hans-Joachim Dulce , Werner Stumpf
IPC分类号： A61K31/195 , A61K31/198 , A61P13/02 , A61P15/00
CPC分类号： A61K31/195 , Y10S514/891
摘要： A method of treating nephro-urological disorders, such as kidney stones, phosphate renal calculi formulation, infections connected with urease formation, and abnormal calcium or phosphate excretion is disclosed. The method comprises administration of L-cysteine, or its acid addition salts, in effective amounts to patients suffering from said disorders. In addition, compositions containing the effective compounds are disclosed.
摘要翻译：公开了一种治疗肾结石，肾结石，磷酸盐肾结石制剂，与脲酶形成有关的感染以及异常的钙或磷酸盐排泄的方法。该方法包括向患有所述疾病的患者施用有效量的L-半胱氨酸或其酸加成盐。此外，公开了含有有效化合物的组合物。

10. 发明授权

US4432992A 4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase 失效
标题翻译：乙醇酸氧化酶的4- [5（和4） - 取代-2-噻吩基] -3-羟基-3-吡咯啉-2,5-二酮抑制剂
公开(公告)号：US4432992A
公开(公告)日：1984-02-21
申请号：US91448
申请日：1979-11-05
申请人： Edward J. Cragoe, Jr. , Clarence S. Rooney , Haydn W. R. Williams
发明人： Edward J. Cragoe, Jr. , Clarence S. Rooney , Haydn W. R. Williams
IPC分类号： C07D333/22 , C07D333/24 , C07D409/04
CPC分类号： C07D409/04 , C07D333/22 , C07D333/24 , Y10S514/891
摘要： Novel 4-[5(and 4)-substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate kidney stone formation. A novel process for their preparation is also disclosed.
摘要翻译：公开了新的4- [5（和4） - 取代-2-噻吩基] -3-羟基-3-吡咯啉-2,5-二酮，其抑制乙醇酸氧化酶，因此可用于治疗和预防草酸钙石块形成。还公开了一种新的制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式